Alliance Global Partners initiated coverage of Quantum-Si (QSI) with a Buy rating and $3.75 price target Connecticut-based Quantum-Si develops and markets the Platinum platform of Next Generation Protein Sequencing machines that currently have Research Use Only status without formal indication approval. The “hook” is the potential to be an early leader in the growing field of protein sequencing and the firm’s belief is that the revenue ramp can accelerate and drive scale and profits, though it considers shares speculative as the company is not yet profitable, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QSI:
- Largest borrow rate increases among liquid names
- Quantum-Si & IDEX Health team on optics module for Proteus instrument
- Supreme Court upholds TikTok ban, Ozempic selected for price talks: Morning Buzz
- Quantum-Si announces inducement grants under Nasdaq listing rule
- Unusually active option classes on open January 8th
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue